Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.

Soares EA, Santos AF, Gonzalez LM, Lalonde MS, Tebit DM, Tanuri A, Arts EJ, Soares MA.

J Antimicrob Chemother. 2009 Nov;64(5):938-44. doi: 10.1093/jac/dkp315. Epub 2009 Aug 26.

PMID:
19710076
2.

Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.

Gonzalez LM, Santos AF, Abecasis AB, Van Laethem K, Soares EA, Deforche K, Tanuri A, Camacho R, Vandamme AM, Soares MA.

J Antimicrob Chemother. 2008 Jun;61(6):1201-4. doi: 10.1093/jac/dkn099. Epub 2008 Mar 20.

PMID:
18356151
3.
4.

Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.

Santos AF, Abecasis AB, Vandamme AM, Camacho RJ, Soares MA.

J Antimicrob Chemother. 2009 Mar;63(3):593-9. doi: 10.1093/jac/dkn526. Epub 2009 Jan 10.

PMID:
19136678
5.

Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.

Gonzalez LM, Aguiar RS, Afonso A, Brindeiro PA, Arruda MB, Soares MA, Brindeiro RM, Tanuri A.

J Gen Virol. 2006 May;87(Pt 5):1303-9.

PMID:
16603533
6.

HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.

Palma AC, Covens K, Snoeck J, Vandamme AM, Camacho RJ, Van Laethem K.

J Antimicrob Chemother. 2012 May;67(5):1075-9. doi: 10.1093/jac/dks010. Epub 2012 Feb 13.

PMID:
22331593
7.

Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.

Holguín A, Paxinos E, Hertogs K, Womac C, Soriano V.

J Clin Virol. 2004 Nov;31(3):215-20.

PMID:
15465415
8.

Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.

Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A, Soriano V, Lal R, Dondero T.

AIDS. 2000 Jul 28;14(11):1489-95.

PMID:
10983635
9.

Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

Nijhuis M, Wensing AM, Bierman WF, de Jong D, Kagan R, Fun A, Jaspers CA, Schurink KA, van Agtmael MA, Boucher CA.

J Infect Dis. 2009 Sep 1;200(5):698-709. doi: 10.1086/605329.

PMID:
19627247
11.

Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M.

Antivir Ther. 2000 Mar;5(1):7-14.

PMID:
10846586
13.

Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses.

Ibe S, Fujisaki S, Fujisaki S, Morishita T, Kaneda T.

Microbiol Immunol. 2006;50(10):765-72.

14.
15.

Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.

Kozal MJ, Hullsiek KH, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

Antivir Ther. 2006;11(4):457-63.

PMID:
16856619
16.

Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.

Palma AC, Abecasis AB, Vercauteren J, Carvalho AP, Cabanas J, Vandamme AM, Camacho RJ.

Infect Genet Evol. 2010 Apr;10(3):373-9. doi: 10.1016/j.meegid.2009.06.019. Epub 2009 Jul 2.

PMID:
19577015
18.

Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes.

Asahchop EL, Oliveira M, Brenner BG, Martinez-Cajas JL, Toni Td, Ntemgwa M, Moisi D, Dandache S, Stranix B, Tremblay CL, Wainberg MA.

Antiviral Res. 2010 Sep;87(3):367-72. doi: 10.1016/j.antiviral.2010.06.001. Epub 2010 Jun 10.

PMID:
20541566
19.

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.

Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V, Larder BA.

AIDS. 2000 Jun 16;14(9):1203-10.

PMID:
10894285
20.

Supplemental Content

Support Center